Effect of Adipokines in Hemodialysis Patients

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double blinded randomized clinical trial of pioglitazone vs. placebo in overweight or obese, diabetic and non-diabetic hemodialysis patients. This study will examine whether pioglitazone modulates adipokine production by adipose tissue in hemodialysis patients and whether these changes result in reduction of inflammation, insulin resistance and oxidative stress and increase in muscle mass.

In addition, this study will also examine the associations of adiposity with adipokines and the metabolic milieu in hemodialysis patients to better understand the biology of adipocytes in uremic milieu.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Overweight (Body Mass Index ≥ 25 kilograms per meter squared (kg/m2))

• Adult (18 years or older)

• Chronic hemodialysis patient

• Diabetic (type 2) or insulin resistant

Exclusion Criteria:

• <18 years old

• No insulin resistance

• Active liver disease

• Class III or IV New York Heart Association heart failure

• Macular edema or hard exudates near macula on fundoscopy

• Current active malignancy (excluding squamous and basal cell skin cancers)

• Active AIDS

• Chronic lung disease requiring supplemental oxygen therapy

• Enrolled in interventional trials using drugs or devices

• Bone break of long bones, vertebrae, or hips in the past three years